- Business Wire•2 days ago
BioTime, Inc. , a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd., today announced that an abstract evaluating OpRegen® in patients with advanced dry Age-Related Macular Degeneration based on the ongoing Phase I/IIa clinical trial will be presented at the Association for Research in Vision and Opthalmology meeting ...
- Capital Cube•9 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioTime, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
- Business Wire•18 days agoBioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
BioTime, Inc. , a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cell Cure Neurosciences Ltd, today dedicated a new, 800 square meter , state-of-the-art, cGMP manufacturing center located in the Jerusalem Bio Park on the campus of Hadassah University Hospital in Jerusalem.
BTX : Summary for BioTime, Inc. Common Stock - Yahoo Finance
BioTime, Inc. (BTX)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||3.21 - 3.37|
|52 Week Range||2.02 - 4.01|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||12.62|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|